Exclusive | GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business
GE HealthCare is acquiring radiopharmaceutical maker Sofie Biosciences for $945 million to expand its medical-imaging business.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
GE HealthCare announced a cash deal to acquire Sofie Biosciences to strengthen its radiopharmaceutical and PET imaging business. Trilantic North America reached an agreement for the sale of Sofie Biosciences to GE HealthCare.
Following the announcement, financial analysts reiterated their stock ratings for GE HealthCare as the radiopharmaceuticals market gained momentum.
Epilogue added 41d ago, after coverage quieted.
The brief
According to coverage from outlets including the Wall Street Journal, CNBC, Barron's, and Investing.com India, GE HealthCare is moving to acquire Sofie Biosciences for a valuation of $945 million, an agreement described in reports as nearly $1 billion. The transaction centers on the acquisition of the radiopharmaceutical maker, a deal that aims to strengthen GE HealthCare's medical-imaging business and establish what corporate announcements term a final mile footprint for PET radiopharmaceutical supply within the United States. Coverage across multiple platforms, such as Business Wire, BioSpace, and qz.com, heavily emphasizes the strategic positioning of the transaction. Analysts and financial reports note that the move is designed to bolster the company's radiopharma operations.
In tandem with the acquisition news, financial institutions have weighed in, with Needham specifically reiterating its stock rating on GE HealthCare in light of the Sofie Biosciences purchase. The background context provided by the reporting highlights the growing corporate interest in radiopharmaceuticals and advanced medical imaging supplies. As demand for specialized diagnostic tools increases, major industry players are actively positioning themselves within the supply chain. The transaction reflects an ongoing industry focus on securing critical infrastructure, particularly regarding positron emission tomography, or PET, diagnostic capabilities in the United States market.
Future developments will depend on the progression of the acquisition process as reported by financial news sources. Readers and market watchers should follow updates regarding regulatory approvals, finalization procedures, and any subsequent commentary from financial analysts or stock rating firms regarding the integration of Sofie Biosciences into GE HealthCare's medical-imaging portfolio.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43d ago.
Quick answers
Who is acquiring Sofie Biosciences?
GE HealthCare is acquiring Sofie Biosciences.
What is the financial value of the acquisition?
The deal is valued at $945 million, described in coverage as nearly $1 billion.
Which financial firm reiterated its stock rating following the announcement?
Needham reiterated its stock rating on GE HealthCare in relation to the acquisition.
Coverage (17)
- Radiopharmaceuticals Market Gains Momentum as GE HealthCare Announces US$945 Million SOFIE Acquisition openPR.com · 43d ago
- GE Healthcare's Sofie Deal to Vertically Integrate Radiopharma Portfolio, Needham Says Yahoo Finance · 43d ago
- GE HealthCare makes $945M acquisition to bolster its PET business The Business Journals · 43d ago
- Needham reiterates GE HealthCare stock rating on Sofie acquisition Investing.com · 43d ago
- GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S. GE HealthCare · 43d ago
- Needham reiterates GE HealthCare stock rating on Sofie acquisition By Investing.com Investing.com South Africa · 43d ago
- Trilantic North America inks $945m sale of SOFIE Biosciences to GE HealthCare pehub.com · 43d ago
- GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business Reuters · 43d ago
- GE HealthCare pays $945M to bolster fast-growing imaging drug business Crain's Chicago Business · 43d ago
- GE Healthcare to Acquire Sofie Biosciences in $945 Million Cash Deal marketscreener.com · 43d ago
- Needham reiterates GE HealthCare stock rating on Sofie acquisition By Investing.com Investing.com India · 43d ago
- GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S. Business Wire · 43d ago
- GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S. BioSpace · 43d ago
- Why GE HealthCare’s $945 Million Sofie Biosciences Deal Makes Sense Barron's · 43d ago
- GE HealthCare is buying radiopharmaceutical maker Sofie Biosciences for $945 million qz.com · 43d ago
- GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business CNBC · 43d ago
- Exclusive | GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business WSJ · 43d ago
Topics
Related trends
Nvidia's Huang signals willingness to return as CEO; board creates national security panel
Jensen Huang says he would be honored to return as Nvidia CEO if the board asks, in his first statement since being unseated last week.
Trump’s New A.I. Chip Rules Rattle Southeast Asia
New Commerce Department chip export rules reported by the Wall Street Journal rattle markets across Southeast Asia.
Putin’s prized bridge is partially destroyed in Ukrainian strike
Ukraine damages Putin's Crimea bridge as Russia strikes vital Kyiv crossings in latest developments.
Leaked Records Show Deutsche Bank Courting Russian Oligarchs
Deutsche Bank shares fell following massive whistleblower leaks detailing Russian oligarch dealings and internal chaos.
Disney expected to post another strong earnings report, led by experiences and streaming
Disney reports fiscal Q4 earnings before the bell on November 17 with investors focused on streaming profitability and Experiences segment strength.
Game over, man?
Nvidia faces leadership upheaval and stock pressure as Jensen Huang departs amid a $2.9 trillion market wipeout and rising political risk.